Mabpharm

Mabpharm Current Assets

The Current Assets of Mabpharm (2181.HK) as of Oct 12, 2026 is 270.55 M CNY. In the previous year, Current Assets was 334.34 M CNY — a change of -19.08% (lower).

Current Assets

270.55 MCNY

YoY

-19.08%

Last updated:

Current Assets of Mabpharm is 2025 270.55 M CNY. Current Assets of Mabpharm was 2024 334.34 M CNY. It decreases by -19.08% lower compared to the previous year.

The Mabpharm Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
260.75 M CNY
Jan 1, 2019
948.25 M CNY
Jan 1, 2020
567.90 M CNY
Jan 1, 2021
262.91 M CNY
Jan 1, 2022
204.47 M CNY
Jan 1, 2023
319.81 M CNY
Jan 1, 2024
334.34 M CNY
Jan 1, 2025
270.55 M CNY
The Mabpharm Current Assets history
YEARCurrent AssetsYoY
270.55 MCNY-19.08%
334.34 MCNY+4.55%
319.81 MCNY+56.41%
204.47 MCNY-22.23%
262.91 MCNY-53.70%
567.90 MCNY-40.11%
948.25 MCNY+263.66%
260.75 MCNY+68.83%
154.45 MCNY—
Access this data via the Eulerpool API

Mabpharm Stock analysis

What does Mabpharm do? Mabpharm Ltd is a biopharmaceutical company based in Suzhou, China. The company was founded in 2009 and specializes in the development and production of monoclonal antibodies. The business model of Mabpharm is to develop, produce, and sell high-quality biological drugs worldwide. The company works closely with customers to understand their needs and provide customized solutions. Mabpharm is divided into different divisions, each specialized in producing specific products. The main ones are oncology, immunology, cardiology, and infectious diseases. Each division offers a portfolio of products tailored to the needs of patients. In the field of oncology, Mabpharm offers a range of monoclonal antibodies that can be used to treat cancer. This includes therapies for breast cancer, gastric cancer, colorectal cancer, and lung cancer. The products have all been developed in collaboration with renowned partners worldwide and undergo rigorous clinical testing before being brought to market. Mabpharm's immunology division focuses on developing drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The products in this division have been specifically designed to regulate the immune system and suppress inflammation symptoms. The cardiology division of Mabpharm is dedicated to the development of drugs for the prevention and treatment of cardiovascular diseases. The products include antibodies for the treatment of lipid metabolism disorders and blood clots. Mabpharm's cardiovascular products also include a cholesterol-lowering medication that helps prevent heart attacks and strokes. In the infectious diseases division, Mabpharm has developed products for the treatment of hepatitis B and hepatitis C. These can reduce viral load and improve liver function. Furthermore, Mabpharm is also involved in the development of vaccines against COVID-19. Mabpharm has become a leading provider of monoclonal antibodies and biological drugs in China and internationally. The company works closely with academics and researchers to find innovative solutions and stay up to date with the latest scientific advancements. In conclusion, Mabpharm is an innovative company specializing in the research and development of biological drugs of all kinds. The company has a wide range of products that have been developed to meet the needs of patients worldwide. Mabpharm has emerged as a key player in the global market for biological drugs in recent years and is a company to watch when it comes to the future of biotechnology. Mabpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mabpharm stock

Current Assets of Mabpharm is 270.55 M CNY in 2025.

Current Assets of Mabpharm changed from 334.34 M CNY to 270.55 M CNY, representing a -19.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Mabpharm since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Mabpharm historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Mabpharm

All Key Metrics — Mabpharm